Abstract：Objective To investigate the clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window. Methods A total of 96 patients with acute cerebral infarction over thrombolysis time window in Zhuanghe Central Hospital, Liaoning Province from September 2018 to March 2020 were selected as the research subjects. They were divided into a reference group (48 cases) and a joint group (48 cases)according to the random number table method. Patients in the reference group were treated with conventional symptomatic treatment + Dipyridamole via intravenous drips, while patients in the joint group were treated with conventional symptomatic treatment + Dipyridamole + Shuxuening via intravenous drips. Neurological function, limb function, daily live activity ability, efficacy, improvement of coagulation indexes and incidence of adverse reactions were compared between the two groups. Results After treatment, the scores of National Institutes of Health stroke scale (NIHSS) in the joint group were lower than those in the reference group, with statistically significant different (P＜0.05). The scores of Fugl-Meyer assessment scale (FMAS) and activity of daily living scale (ADL) in the joint group were higher than those in the reference group, the differences were statistically significant (P＜0.05). The total effective rate of the joint group was higher than that of the reference group, with statistically significant different (P＜0.05). After treatment, the prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) in the joint group were longer than those in the reference group, and fibrinogen (FIB) in the joint group was lower than that in the reference group,the differences were statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion The application of dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction patients over thrombolysis time window has a significant effect, and the neurological function, limb function, life activity ability and coagulation indexes have been significantly improved, with few adverse reactions, which is safe and reliable.
林淑春. 双嘧达莫联合舒血宁治疗超溶栓时间窗急性脑梗死的临床效果[J]. 中国当代医药, 2021, 28(28): 107-110.
LIN Shu-chun. Clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window. 中国当代医药, 2021, 28(28): 107-110.
京公网安备 11010502046607号